Reytor Gonzalez , Claudia MariaSimancas Racines , Daniel AlejandroRomán Galeano , Náthaly MercedesVásquez , Juan PabloJima Gavilanes , Dolores AlexandraRupalakshmi , Vijayan2026-07-152026-07-15202612/12/2025"Citation: Simancas-Racines, D.;Román-Galeano, N.M.; Vásquez, J.P.;Jima Gavilanes, D.; Vijayan, R.;Reytor-González, C. Liquid Biopsy and Multi-Omic Biomarkers in BreastCancer: Innovations in EarlyDetection, Therapy Guidance, and Disease Monitoring. Biomedicines 2025, 13, 3073. https://doi.org/10.3390/biomedicines13123073"2227-9059https://doi.org/10.3390/biomedicines13123073https://www.mdpi.com/2227-9059/13/12/3073https://repositorio.puce.edu.ec/handle/123456789/49336Liquid biopsy and multi-omic biomarker integration are transforming precision oncology in breast cancer, providing real-time, minimally invasive insights into tumor biology. By analyzing circulating tumor DNA, circulating tumor cells, exosomal non-coding RNAs, and proteomic or metabolomic profiles, clinicians can monitor clonal evolution, therapeutic response, and recurrence risk in real time. Recent advances in sequencing technologies, methylation profiling, and artificial intelligence–driven data integration have markedly improved diagnostic sensitivity and predictive accuracy. Multi-omic frameworks com bining genomic, transcriptomic, and proteomic data enable early detection of resistance, molecular stratification, and identification of actionable targets, while machine learning models enhance outcome prediction and therapy optimization. Despite these advances, key challenges persist. Pre-analytical variability, lack of standardized protocols, and disparities in access continue to limit reproducibility and clinical adoption. High costs, incomplete regulatory validation, and the absence of definitive evidence for mortality reduction un derscore the need for larger, prospective trials. Integrating multi-omic assays into clinical workflows will require robust bioinformatics pipelines, clinician-friendly reporting sys tems, and interdisciplinary collaboration among molecular scientists, data engineers, and oncologists. In the near future, liquid biopsy is expected to complement, not replace, traditional tissue analysis, serving as a cornerstone of adaptive cancer management. As sequencing becomes faster and more affordable, multi-omic and AI-driven analyses will allow earlier detection, more precise treatment adjustments, and continuous monitoring across the disease course. Ultimately, these innovations herald a shift toward real-time, data-driven oncology that personalizes breast cancer care and improves patient outcomes.enBreast cancerMulti-omic biomarkersLiquid biopsyPrecision medicineHealthcareArtículo científico